Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 16/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 14/20 | 0.71 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | ACR | P10323 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18184045 | 0.89 | CSNK1E (0.88) | CSNK1ECSNK1D | |
| SCHEMBL18171175 | 0.88 | CSNK1E (0.57) | CSNK1ECSNK1DTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL16728859 | 0.84 | CSNK1E (0.73) | CSNK1ECSNK1D | |
| SCHEMBL18171164 | 0.83 | CSNK1E (1.00) | CSNK1ECSNK1D | |
| SCHEMBL16722553 | 0.81 | CSNK1E (0.65) | CSNK1ECSNK1DTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL16722730 | 0.79 | CSNK1E (0.82) | CSNK1ECSNK1D | |
| SCHEMBL18184044 | 0.78 | CSNK1E (0.69) | CSNK1ECSNK1DRIPK2 | |
| SCHEMBL16722740 | 0.78 | CSNK1E (0.52) | CSNK1ECSNK1DTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL18171259 | 0.78 | CSNK1E (0.63) | CSNK1ECSNK1DTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL16700761 | 0.77 | CSNK1E (0.62) | CSNK1ECSNK1DTAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068784-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9598423-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1A1, CSNK1E, CSNK1G1 | CSNK1E 2/4885CSNK1D 6/4885TAS1R3 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.